JPRN-UMIN000002817招募中未知
Prophylaxis of acute GVHD after bone marrow transplantation from unrelated donors with C3 monitoring of cyclosporine: a multicenter prospective study. - Prophylaxis of acute GVHD with C3 monitoring of cyclosporine.
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science0 个研究点目标入组 70 人开始时间: 2009年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 55years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Non-myeloablative allogeneic transplantation 2) Past transplantation history 3) T-cell depleted transplantation 4) Use of ATG or ALG as preparative regimens 5) Serum creatinine level >= 2.0 mg/dL or >= 1.5 times the upper limit of the normal range, Ccr < 50 mL/min 6) Serum total bilirubin level >= 2.0 mg/dL, serum AST/ALT level >= 2 times the upper limit of the normal range 7) Uncontrolled hypertension 8) Uncontrolled diabetes mellitus on insulin therapy 9) Uncontrolled active infections 10) History of epilepsy 11) Other severe complications 12) Pregnant female 13) Allergic to cyclosporine 14) Any patients who are judged unsuitable for the enrollment by the attending physician
研究者
相似试验
进行中（未招募）
1 期
Preventie van ernstige Graft versus Host ziekte na allogene stamcel transplantatie gegeven als immuuntherapie voor patienten met een hematologische ziekte. Een gerandomiseerde fase III studie (HOVON 96 GVHD).Graft versus Host DiseaseMedDRA version: 20.0Level: LLTClassification code 10018799Term: GVHDSystem Organ Class: 100000004870EUCTR2008-003540-11-NLHOVON Foundation500
已完成
3 期
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial.Graft versus Host Disease10018849NL-OMON47822HOVO497
进行中（未招募）
不适用
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial. - HOVON 96 GVHDGraft versus Host DiseaseEUCTR2008-003540-11-BEHOVON Foundation500
招募中
不适用
Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase III trial.Randomization 1: Patients planned to undergo an allogeneic SCT formalignant hematological disorders and with a related or unrelated 8/8 HLA matched donor.NL-OMON28315Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl500
进行中（未招募）
不适用
Treatment of severe acute GVHD after allogeneic hematopoietic stem cell transplantation with steroids versus MSC and steroids.A prospective double-blind placebo-controlled randomized phase III trialGraft Versus Host DiseaseMedDRA version: 18.0Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 18.0Level: LLTClassification code 10068908Term: AGVHDSystem Organ Class: 10021428 - Immune system disordersEUCTR2011-003237-33-NLHOVON Foundation200